Similarly, another study assessing mutation frequencies in 81 HCC tumor samples by NGS observed that high TMB is associated with mutations in five specific genes: TP53, CTNNB1, AT-rich interactive domain-containing protein 1A (ARID1A), myeloid/lymphoid or mixed-lineage leukemia (MLL), and nuclear receptor co-repressor 1 (NCOR1), and that high TMB and these associated mutations may represent potentially effective biomarkers for the prediction of ICI therapy outcome [99]. This evidence concerns the gene ARID1A and hepatocellular carcinoma.